J. Pharm. Pharmacogn. Res., vol. 14, no. 5, Article ID 2594, Sep-Oct 2026.

DOI: https://doi.org/10.56499/jppres_14.5.2594

Review

Active hexose correlated compound in ovarian cancer: A systematic review of clinical and preclinical evidence

[Compuesto correlacionado de hexosa activa en el cáncer de ovario: revisión sistemática de la evidencia clínica y preclínica]

Munizar Munizar1*, Teuku Heriansyah2, Imran Imran3, Marwan Ramli4, Sofia Sofia5

1Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia.

2Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.

3Department of Neurology, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.

4Department of Mathematics, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.

5Environmental Health Division, Department of Public Health, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia.

*E-mail: munizar.nb@gmail.com, munizarlbfk@usk.ac.id

Abstract

Context: Ovarian cancer is commonly diagnosed at an advanced stage and remains associated with high recurrence, limited survival, and treatment-related toxicity. Active hexose correlated compound (AHCC), a standardized extract of cultured Lentinula edodes mycelia, has been investigated as a possible adjunct to chemotherapy because of its immunomodulatory and antitumor properties.

Aims: To systematically synthesize the available clinical and preclinical evidence on the effects of AHCC in ovarian cancer.

Methods: PRISMA-guided searches were performed in PubMed, ScienceDirect, the Cochrane Library, and Google Scholar up to 20 August 2025. Eligible studies evaluated AHCC in ovarian cancer or related experimental models. Clinical and preclinical evidence were synthesized narratively because of substantial heterogeneity.

Results: Four studies were included: two clinical studies and two preclinical studies. One randomized trial in ovarian/peritoneal cancer suggested preservation of CD8+ T-cell levels and reduced nausea and vomiting during chemotherapy. One before–after study in mixed advanced cancers, including a small ovarian subgroup, suggested reduced hematologic and hepatic toxicity and improved quality of life. Preclinical studies showed inhibition of ovarian cancer cell proliferation, induction of apoptosis, suppression of STAT3 signaling, and enhanced response to pegylated liposomal doxorubicin. No study reported progression-free survival or overall survival.

Conclusions: AHCC showed preliminary biological activity and possible supportive effects during chemotherapy, but the clinical evidence remained very limited. Larger, well-designed ovarian cancer trials are required.

Keywords: complementary therapies; dietary supplements; immunomodulation; ovarian neoplasms; shiitake mushrooms; signal transducer and activator of transcription 3.

PDF Download

Resumen

Contexto: El cáncer de ovario suele diagnosticarse en estadios avanzados y se asocia con alta recurrencia, supervivencia limitada y toxicidad por el tratamiento. El compuesto correlacionado con hexosa activa (AHCC), un extracto estandarizado del micelio cultivado de Lentinula edodes, se ha investigado como posible complemento de la quimioterapia por sus propiedades inmunomoduladoras y antitumorales.

Objetivos: Sintetizar sistemáticamente la evidencia clínica y preclínica disponible sobre los efectos del AHCC en el cáncer de ovario.

Métodos: Se realizaron búsquedas guiadas por PRISMA en PubMed, ScienceDirect, la Biblioteca Cochrane y Google Scholar hasta el 20 de agosto de 2025. Se incluyeron estudios sobre el AHCC en cáncer de ovario o en modelos experimentales relacionados con el cáncer de ovario. La evidencia clínica y preclínica se sintetizó de forma narrativa debido a la heterogeneidad.

Resultados: Se incluyeron cuatro estudios: dos clínicos y dos preclínicos. Un ensayo aleatorizado en cáncer de ovario/peritoneal sugirió la preservación de linfocitos T CD8+ y una menor incidencia de náuseas y vómitos durante la quimioterapia. Un estudio antes-después en cánceres mixtos avanzados (subgrupo pequeño de ovario) sugirió menor toxicidad hematológica y hepática y una mejor calidad de vida. Los estudios preclínicos mostraron inhibición de la proliferación celular, inducción de apoptosis, supresión de STAT3 y una mayor respuesta a la doxorrubicina liposomal pegilada. Ningún estudio informó sobre supervivencia libre de progresión ni sobre supervivencia global.

Conclusiones: El AHCC mostró actividad biológica preliminar y posibles efectos de apoyo durante la quimioterapia, pero la evidencia clínica fue muy limitada. Se requieren ensayos más amplios en el cáncer de ovario.

Palabras Clave: cáncer de ovario; hongos shiitake; inmunomodulación; suplementos dietéticos; terapias complementarias; transductor de señales y activador de la transcripción 3.

PDF Download

https://jppres.com/jppres/pdf/vol14/jppres_14.5.2594.pdf

Citation Format: Munizar M, Heriansyah T, Imran I, Ramli M, Sofia S (2026) Active hexose correlated compound in ovarian cancer: A systematic review of clinical and preclinical evidence. J Pharm Pharmacogn Res 14(5): 2594. https://doi.org/10.56499/jppres_14.5.2594
References

Atlihan U, Yavuz O, Ata C, Avsar HA, Bildaci TB, Ozay AC, Ersak B, Solmaz U, Erkilinc S (2025) Evaluation of the efficacy of active hexose correlated compound as an adjuvant in reducing recurrence after condyloma cauterization. Medicina (Kaunas) 61(4): 622. https://doi.org/10.3390/medicina61040622

Banerjee S, Moore KN, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22(12): 1721–1731. https://doi.org/10.1016/S1470-2045(21)00531-3

Choi JY, Lee S, Yun SM, Suh DH, Kim K, No JH, Jeong EH, Kim YB (2018) Active hexose correlated compound (AHCC) inhibits the proliferation of ovarian cancer cells by suppressing signal transducer and activator of transcription 3 (STAT3) activation. Nutr Cancer 70(1): 109–115. https://doi.org/10.1080/01635581.2018.1380203

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81(1): 17–38. https://doi.org/10.1007/s00280-017-3501-8

Greening S, Sood N, Nicum S (2022) The challenges and opportunities in ovarian cancer relapse—the role of second and third-line chemotherapy: Literature review. Gynecol Pelvic Med 5: 15. https://doi.org/10.21037/gpm-21-29

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008) GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650): 924–926. https://doi.org/10.1136/bmj.39489.470347.AD

Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol 14: 43. https://doi.org/10.1186/1471-2288-14-43

Hunter RJ, Fujii H, Wakame K, Gaikwad A, Wolf JK, Smith JA (2011) Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod 4(3): 6–14.

Ito T, Urushima H, Sakaue M, Yukawa S, Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T, Kondo K (2014) Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC), in patients with advanced cancer during chemotherapy: The significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr Cancer 66(3): 377–382. https://doi.org/10.1080/01635581.2014.884232

Lee WW, Lee N, Fujii H, Kang I (2012) Active hexose correlated compound promotes T helper (Th)17 and 1 cell responses via inducing IL-1beta production from monocytes in humans. Cell Immunol 275(1-2): 19–23. https://doi.org/10.1016/j.cellimm.2012.04.001

Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, Zhu X (2020) STAT3 signaling in ovarian cancer: A potential therapeutic target. J Cancer 11(4): 837–848. https://doi.org/10.7150/jca.35011

Merchand-Reyes G, Santhanam R, Valencia-Pena ML, Kumar K, Mo X, Belay T, Woyach JA, Mundy-Bosse B, Tridandapani S, Butchar JP (2023) Active hexose-correlated compound shows direct and indirect effects against chronic lymphocytic leukemia. Nutrients 15(24): 5138. https://doi.org/10.3390/nu15245138

Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Lorusso D (2021) Ovarian cancer treatments strategy: focus on PARP inhibitors and immune check point inhibitors. Cancers (Basel) 13(6): 1298. https://doi.org/10.3390/cancers13061298

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 18(3): e1003583. https://doi.org/10.1371/journal.pmed.1003583

Park HJ, Boo S, Park I, Shin MS, Takahashi T, Takanari J, Homma K, Kang I (2022) AHCC®, a standardized extract of cultured Lentinula edodes mycelia, promotes the antitumor effect of dual immune checkpoint blockade effect in murine colon cancer. Front Immunol 13: 875872. https://doi.org/10.3389/fimmu.2022.875872

Salas Bolívar P, Gonzalez-Benitez C, Carbonell López M, Díez Sebastian J, Hernández Gutiérrez A, Zapardiel I (2025) Prognostic factors after the first recurrence of ovarian cancer. J Clin Med 14(2): 470. https://doi.org/10.3390/jcm14020470

Sato S, Miura T, Ogasawara A, Shintani D, Yamaguchi S, Inui H, Yoshinaga A, Nishiyama M, Tsugane M, Hasegawa K (2025) Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential. J Gynecol Oncol 36(2): e24. https://doi.org/10.3802/jgo.2025.36.e24

Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H (2009) Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol 8(1): 43–51.

Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA III, Bai Y, Olsen RJ, Byrd TT (2022) AHCC supplementation to support immune function to clear persistent human papillomavirus infections. Front Oncol 12: 881902. https://doi.org/10.3389/fonc.2022.881902

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355: i4919. https://doi.org/10.1136/bmj.i4919

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: l4898. https://doi.org/10.1136/bmj.l4898

Suknikhom W, Lertkhachonsuk R, Manchana T (2017) The effects of active hexose correlated compound (AHCC) on levels of CD4+ and CD8+ in patients with epithelial ovarian cancer or peritoneal cancer receiving platinum-based chemotherapy. Asian Pac J Cancer Prev 18(3): 633–638. https://doi.org/10.22034/APJCP.2017.18.3.633

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3): 209–249. https://doi.org/10.3322/caac.21660

Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y (2008) Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer 60(5): 643–651. https://doi.org/10.1080/01635580801993280

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M (2016) Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutr Cancer 68(2): 234–240. https://doi.org/10.1080/01635581.2016.1134597

Yin Z, Fujii H, Walshe T (2010) Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-gamma and/or tumor necrosis factor-alpha in healthy adults. Hum Immunol 71(12): 1187–1190. https://doi.org/10.1016/j.humimm.2010.08.006

© 2026 Journal of Pharmacy & Pharmacognosy Research

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Site Update: October 25th, 2026

Made with ♥ by AVAGAX Studio